Form 4: Vyome Holdings Director Acquires Shares Post-Merger

Mohanjit Jolly, a director of Vyome Holdings, Inc., reported the indirect acquisition of 454,456 shares of common stock following the merger of Vyome Therapeutics, Inc. into a subsidiary of the Issuer.

Summary

• Mohanjit Jolly, a director of Vyome Holdings, Inc., reported the indirect acquisition of 454,456 shares of the Issuer's common stock.
• The acquisition occurred on August 15, 2025, as a result of a merger between Raider Lifesciences Inc. (a wholly owned subsidiary of the Issuer) and Vyome Therapeutics, Inc.
• Under the Agreement and Plan of Merger, dated July 8, 2024, each 5,000 shares of Vyome Therapeutics common and preferred stock were converted into 1 share of the Issuer's common stock.
• The Issuer was renamed "Vyome Holdings, Inc." following the merger, with Vyome Therapeutics continuing as a subsidiary.
• Mohanjit Jolly received these 454,456 shares in exchange for 2,272,280,000 shares of Vyome Therapeutics common stock.
• The shares are beneficially owned indirectly through Iron Pillar Fund I Ltd., where Mohanjit Jolly serves as a general partner.

Sentiment

Score: 7

Explanation: The completion of a merger and a director's subsequent acquisition of shares, albeit indirectly, typically signals a positive corporate event and confidence in the combined entity's future.

Positives

• The completion of the merger between Vyome Therapeutics, Inc. and Raider Lifesciences Inc. (a subsidiary of Vyome Holdings, Inc.) indicates a strategic consolidation.
• Mohanjit Jolly, a director, increased his beneficial ownership in the combined entity, potentially signaling confidence in the new Vyome Holdings, Inc.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance, as it is a historical report of a transaction.

Management Comments

• Mohanjit Jolly is a general partner of Iron Pillar Fund I Ltd. and an advisor to and representative of Iron Pillar India Fund I for investments in the Issuer.

Industry Context

The merger and subsequent stock conversion indicate consolidation within the biotechnology or pharmaceutical sector, potentially aiming for increased market presence or operational synergies. This is a common strategy in industries requiring significant R&D and capital.

Stakeholder Impact

• Shareholders: Existing shareholders of Vyome Therapeutics had their shares converted into Vyome Holdings stock, impacting their ownership structure and potentially the value of their holdings. New shareholders of Vyome Holdings (post-merger) now own a combined entity.

Key Dates

Keywords

Vyome Holdings, HIND, Mohanjit Jolly, Merger, Stock Acquisition, Form 4, Beneficial Ownership, Vyome Therapeutics, Iron Pillar Fund